CTC tests for cancer - Oncotrace | RGCC Southeast Asia

Oncotrace

Charting a course for cancer-free future

Oncotrace is an important step in the management and follow-up of a cancer treatment regimen. At the initial phase of the diagnosis of cancer, it gives us information on the current CTC count as well as the profile of how aggressive these cells are through the study of the Cancer Stem Cell (CSC) markers. By studying cancer behavior at a molecular level, doctors and patients can monitor the activity of tumor markers responsible for migration, proliferation, resistance, and metastasis.

How does Oncotrace work?

The Oncotrace test establishes a baseline measurement of your cancer status at the beginning of treatment which is used as a reference point to monitor the treatment.

A blood sample is taken to examine the presence and amount of circulating tumor cells.

Albeit more important is the nature of the CTCs, this would tell us how aggressive or benign the tumor cells are.

This is called immunophenotyping. This analysis unravels vital information on the cancer's nature, probability of metastatic spread, and likelihood of being chemo resistant.

What details does the test provide?

CTC Count

This test identifies and measures the circulating tumor cells (CTC) count in the blood. The test helps establish a baseline count before treatment. Monitoring CTC count during and after treatment helps gauge the effectiveness of treatment.

A rise in CTC indicates the treatment is not working, while a decline means the treatment is effective. It guides clinicians in making the necessary treatment adjustments.

Phenotype Markers

Oncotrace also reveals phenotype markers that indicate the tissue origin of tumor cells.

Particularly beneficial for patients with multiple primary tumors, these markers aid in screening, diagnosis, staging, prognosis, treatment response monitoring, and recurrence evaluation.

Stemness Markers

The test also identifies stemness markers associated with cancer behavior and activity in the bloodstream. Even with low CTC counts, active stemness markers mean the cancer is still active.

In early cancer, active stemness markers indicate potential proliferation.

In active cancer, the activity of markers suggests the risk of metastasis.

In cancer remission, active markers indicate the possibility of recurrence.

How does it help?

Follow-up tool to monitor the cancer disease burden.

Assessment of cancer treatment response.

Early warning test for relapse and recurrence.

Cancer Stem Cell (CSC) markers study on specific cancer will help us to monitor the nature of the tumor behavior.

Personalize your cancer journey

Reserve your 30-minute free consultation

Why choose Oncotrace?

It identifies the nature and number of CTCs, giving you an idea of how advanced or benign cancer is. It also informs us of the likelihood of metastatic spread. It helps in monitoring and understanding the disease progression, facilitating timely intervention.

It would also inform the treating physician if current management were effective vs ineffective, allowing changes to a current protocol if it's not working well.

With this test, the physician and the patient would have insights into the current effectiveness of a particular treatment and whether any changes need to be made.

Test details

To whom it is relevant: The test is ideal for the patients currently undergoing cancer treatment or had cancer in the past

Talk to our RGCC experts

Whatsapp me the Oncotrace sample report

Testimonials

"RGCC's Oncotrace test offered me peace of mind in a time of uncertainty. Knowing I have a tool to monitor for cancer recurrence allows me to focus on living my life to the fullest.

"Wiith early detection of recurrence too, the test can say whether the treatment is working or not. I experience it myself."